Abstract
Vitiligo is characterised by well demarcated, cutaneous, macular depigmentation, with worldwide prevalence estimated to be between 0.2-1.8% [1]. Vitiligo treatments aim to encourage re-pigmentation and include topical corticosteroids, calcineurin inhibitors and NB-UVB phototherapy. Camouflage can also be prescribed to help mask the appearance of vitiligo, although this is frequently only prescribed for the face.
This article is protected by copyright. All rights reserved.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2hNVOFU
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου